Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Tasipimidine for Patients with Insomnia Disorder

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying insomnia disorder, a condition where individuals have trouble falling asleep or staying asleep. The treatment being tested is called ODM-105, which is an oral solution containing the active substance tasipimidine. The trial will also use an ODM-105 placebo oral solution for comparison purposes.

The purpose of the study is to evaluate how effective tasipimidine is in helping patients with insomnia disorder. Participants in the study will take the medication at bedtime for three consecutive nights. Throughout the study, researchers will monitor various aspects of sleep, such as how long it takes to fall asleep and how often participants wake up during the night. The study will also keep track of any side effects and changes in vital signs like heart rate and blood pressure.

Participants will be asked to report their experiences and any changes in their sleep patterns. The study aims to provide valuable information on the potential benefits and safety of tasipimidine for treating insomnia disorder.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, ensure that the informed consent form is signed. This confirms understanding and agreement to participate in the trial.

    Eligibility is confirmed based on criteria such as age between 18 and 65 years, a diagnosis of insomnia disorder, and specific sleep patterns.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate sleep patterns. This includes a polysomnography (PSG) test, which monitors sleep to measure how long it takes to fall asleep and total sleep time.

    The assessment ensures that the criteria for sleep latency and total sleep time are met.

  3. Step 3

    Medication administration

    The study involves taking an oral solution called ODM-105, which contains the active substance tasipimidine. A placebo solution may also be administered.

    The medication is taken as a 0.3 mg/ml oral solution at bedtime for three consecutive nights.

  4. Step 4

    Monitoring and evaluation

    Throughout the trial, sleep is monitored using polysomnography (PSG) to assess wakefulness after sleep onset and latency to persistent sleep.

    Additional evaluations include monitoring for any adverse events, heart rate, blood pressure, and morning sleepiness.

  5. Step 5

    Completion of the trial

    After completing the medication phase, a final assessment is conducted to evaluate the effects of the treatment.

    The study aims to determine the efficacy and tolerability of tasipimidine in treating insomnia disorder.

Who can join the trial?

10 criteria

  • Signed informed consent for participation in the study.
  • Male or female participants aged between 18 and 65 years at the screening visit.
  • Have **insomnia disorder** as defined by the **Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Text Revision (DSM-5-TR®)**.
  • Have a self-reported history of taking **30 minutes or more to fall asleep** and sleeping **6 hours or less** on at least 3 nights per week for at least 3 months before the screening.
  • Have an **Insomnia Severity Index (ISI©) score** of **15 or higher**. The ISI is a questionnaire used to measure the severity of insomnia.
  • Usual bedtime is between 9:00 PM and 2:00 AM.
  • Regular time spent in bed is between 6 and 9 hours.
  • Meet specific sleep criteria during the 2 screening nights using **polysomnography (PSG)**, a type of sleep study:
    • Average time to fall into a deep sleep (latency to persistent sleep) is **25 minutes or more** (with neither of the 2 nights being less than 15 minutes).
    • Average total sleep time is **6 hours or less**.
    • If sexually active and not permanently sterilized, female participants with a fertile male partner and male participants with female partners who can become pregnant must use a **highly effective form of contraception**. Women who are postmenopausal (1 year since their last menstrual cycle) are considered not to be able to have children and can be included.

Who cannot join the trial?

8 criteria

  • Patients with any other sleep disorders besides insomnia disorder cannot participate. Insomnia disorder is a condition where a person has trouble falling asleep or staying asleep.
  • Patients who are currently using medications that affect sleep or wakefulness cannot participate.
  • Patients with a history of substance abuse or dependence in the past year cannot participate. Substance abuse refers to the harmful use of substances like drugs or alcohol.
  • Patients with any serious medical conditions that are not stable cannot participate. A serious medical condition is one that requires ongoing medical attention and could affect the study.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have participated in another clinical trial within the last 30 days cannot participate.
  • Patients with known allergies to the study medication or similar drugs cannot participate.
  • Patients with a history of psychiatric disorders that are not well-controlled cannot participate. Psychiatric disorders are mental health conditions like depression or anxiety.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tasipimidine is a medication being studied for its potential to help people who have trouble sleeping, a condition known as insomnia disorder. This medication is taken at bedtime, and the trial is looking at how well it works and how well people can tolerate it after taking it for three nights in a row. The goal is to see if tasipimidine can help improve sleep quality and duration for those who struggle with insomnia.

What is already known about the treatment

Tasipimidine – Tasipimidine is administered orally, typically in the form of a tablet taken at bedtime. It is currently being studied in clinical trials for its effectiveness and safety in treating insomnia disorder, a condition characterized by difficulty falling or staying asleep. The medication works by targeting specific receptors in the brain to help regulate sleep patterns and promote restful sleep. Tasipimidine is classified as a sedative-hypnotic, which means it is designed to help induce sleep and improve sleep quality.

Investigated diseases

Insomnia disorder – Insomnia disorder is a condition characterized by difficulty falling asleep, staying asleep, or waking up too early and not being able to return to sleep. It often leads to dissatisfaction with sleep quality and can result in daytime fatigue, mood disturbances, and impaired cognitive function. The disorder can be acute, lasting a few days to weeks, or chronic, persisting for a month or longer. It may occur independently or be associated with other medical or psychiatric conditions. The progression of insomnia disorder can vary, with some individuals experiencing intermittent episodes, while others may have persistent symptoms. Factors such as stress, lifestyle, and environmental changes can influence the severity and frequency of insomnia episodes.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-502483-21-00Protocol code3110012Estimated enrolment302 patientsSponsorOrion Corporation

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.